Ophthalmoplegic migraine (OM) may be diagnosed after recurrent episodes of headache, followed by the paresis of one or more ocular cranial nerves (typically oculomotor 1 ). The diagnosis requires all other causes of focal intracranial neuropathy (i.e. vascular, inflammatory, tumor or infectious etiology), to be excluded. Contrast MR imaging typically reveals enhancement of the affected nerve at the site of its exit from the brainstem. 2 Ophthalmoplegic migraine is rare, with an annual incidence estimated at 0.7 per million. 3 However it does account for up to 7% of all isolated cases of childhood oculomotor nerve palsy. 4, 5 ABSTRACT: Background: This critical review provides a summary of the clinical presentation, neuroimaging, treatment and prognosis in pediatric ophthalmoplegic migraine (OM). The features of OM are not in keeping with its classification as a migraine-variant. Method: We review 3 new and 37 reported pediatric OM cases. Results: Headache was an inconsistent feature, with 25% patients showing no evidence of pain at the initial OM episode. Patients demonstrated: 1) prolonged time for symptom resolution to occur (median time 3 weeks); 2) tendency for recurrent episodes to have more severe and persistent nerve involvement; 3) evidence of permanent neurological sequelae with recurrent episodes (30% of patients); 4) rapid improvement and shortened duration with corticosteroid therapy and; 5) transient, reversible MRI contrast enhancement of the affected cranial nerve (86% of patients). These features would not be expected in primary migraine headache. Conclusion: A detailed understanding of the natural history of OM is essential for the clinical. This review provides support that OM may result from cranial nerve inflammation with headache a secondary and later feature of this condition.
associated irritability, pallor or vomiting may provide indirect evidence of its presence. 8 Controversy has surrounded the underlying mechanism of this disorder. Since episodes are transient and occur in otherwise healthy children, the opportunity does not exist for pathological examination. The early theory of OM attributed the ophthalmoplegia to a compressive neuropathy resulting from the vascular-dilatation phase of migraine. 9 Not only did the "vascular theory" fail to provide an adequate explanation of migraine, so too did it fail to adequately describe the clinical features of OM. Large vessels would cause an extrinsic nerve compression which simply could not account for the frequent sparing of the pupil-response in this condition (pupillary fibres are more superficial and should be affected early with this mechanism). 10 An autopsy study later identified smaller perforating arteries to frequently penetrate cranial nerves. 11 It was postulated that internal or intrinsic compressive effects of the perforating arteries might offer a possible explanation to the clinical heterogeneity of OM, but this theory still failed to explain the radiographic findings. Several other theories have been proposed, including: ischemic neuropathy, 10 recurrent infection, 12 recurrent demyelination-remyelination 6 and/or inflammation. 13 Post-mortem examination of adults, who previously met the criteria for ophthalmoplegic migraine, have demonstrated oculomotor nerve hypertrophy and scar formation in keeping with a recurrent demyelinating or inflammatory process. 13, 14 This paper provides a critical review of 40 cases of ophthalmoplegic migraine summarizing the clinical presentation, neuroradiographic findings and outcome of this condition. The results provide further support for Carlow's theory 13 that ophthalmoplegic migraine is indeed an inflammatory cranial neuropathy with the potential to result in subsequent or secondary head pain. Although the link between cranial nerve inflammation and headache remains unclear, the possibility of trigeminovascular activitation remains a very attractive possibility.
METHODS
Three cases of pediatric ophthalmoplegic migraine were identified from the consulting practice of two child neurologists at the Children's Hospital of Eastern Ontario, Canada (presenting between 1999 -2005). Previous case reports were obtained by a literature search of Pubmed using keywords: "ophthalmoplegic migraine". The bibliography of all case reports were reviewed in an attempt to identify additional patients. All English-language case reports between 1980 -2005 were included. Patients must have been < 18 years old at the time of their initial episode. The following information was extracted; 1) age at time of initial event; 2) cranial nerve involved; 3) time to symptom resolution (initial and recurrent events); 4) type and result of neuroimaging performed; 5) use and result of corticosteroid therapy; 6) family history of migraine and; 7) evidence of permanent neurological damage. Cases that did not describe the physical examination were excluded.
CASE REPORTS

Case 1
A healthy, nine-year-old female presented with abrupt onset right partial oculomotor nerve paresis. She awoke complaining of diploplia and near-complete right ptosis. She had experienced a burning, right eye pain for several days prior, which had resolved prior to onset of ptosis. She denied other types of head pain, nausea, vomiting or photophobia. She was otherwise well with no fever or recent illness. She reported no change in visual acuity. Her medical history noted a two year history of recurrent, intermittent right retro-orbital and/or temporal headaches occurring roughly once per month with no associated symptoms or clear aggravating factors. There was no family history of migraine. Her father developed right Bell's palsy at age 53 with good recovery. On examination, she was alert and wellappearing. Her pupils were equal and briskly reactive to light and there was no relative afferent pupillary defect. Her visual acuity was normal. She had marked impairment of right eye adduction with attempted medial gaze. She had nearly complete right ptosis, being unable to open her right eye more than two millimetres. Her neurological exam was otherwise normal. Her complete blood count (CBC) and sedimentation rate (ESR) were normal. Magnetic resonance imaging (MRI) with gadolinium showed thickening and enhancement of the cisternal portion of her right oculomotor nerve. The MRA was normal. She was treated with prednisone (x 5 days at 2 mg/kg, with subsequent dose-tapering). Re-examination on day 12 noted resolution of the right ptosis with some mild persistent difficulty with right eye adduction. She demonstrated complete clinical recovery over a two month period.
She continued to have intermittent episodes of right eye pain, lasting for several hours and occurring at roughly one month intervals (no association with menstrual cycle). She had no associated nausea, vomiting, photophobia and no ptosis or diplopia.
At age 12 years, she developed a recurrent episode of right eye pain associated with abrupt onset right pupil dilatation, diplopia and incomplete ptosis. On examination, a sluggish right pupillary response to light was noted. At rest, her right eye showed slight downward and lateral deviation, she was unable to fully adduct or elevate her right eye. She had incomplete right ptosis. The remainder of her exam was normal. The MRI with gadolinium showed pronounced thickening of the right oculomotor nerve, with a prominent area of contrast enhancement proximally at the site of exit from the midbrain (Figure 1 ).
Re-examination two months after the second episode noted complete resolution of ptosis, but with persistent mild diplopia. Her visual acuity was 20/20 OD (right) and 20/25 OS (left). Her pupils reacted normally. She had mild persistent right hypotropia, indicating mild residual weakness of right eye elevation. Fundoscopic examination was normal. Her clinical examination was returned to normal by ten weeks after the episode. A follow-up MRI with gadolinium ten weeks after her second episode noted resolution of abnormal enhancement of the right third cranial nerve, but persistent thickening of the previously enhancing segment (Figure 2 ). She has not had a recurrent episode over the past 18 months.
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Case 2
A previously healthy, 12-month-old male presented with abrupt onset left ptosis and eye deviation. He had no preceding headache, pallor or irritability. There was no recent or intercurrent illness. He was otherwise healthy and developmentally normal. Family history of migraine was not present. Examination revealed an alert and well appearing male. His left eye was deviated downward and laterally and he demonstrated incomplete left ptosis. His pupils were equal and briskly reactive to light. His neurological examination was otherwise normal. CBC, ESR and CSF analysis were normal. Chest radiograph and skin tuberculin test (PPD) were negative. Magnetic resonance imaging of the head with gadolinium showed a small (3-4 mm) area of increased enhancement on the anterior surface of the left midbrain/cerebral peduncle at the site of exit of the left oculomotor nerve. The remainder of the brain was normal.
He was treated with prednisone (2mg/kg; x10 days) with tapering over the following week. Rapid clinical improvement was noted in his left ptosis and ocular movements over 2-3 days. A repeat MRI with gadolinium three months later was normal.
He had two recurrent episodes at 17 and 23-months-of-age. They were identical in nature; abrupt in onset, with no preceding headache, irritability or pallor. Partial left oculomotor paresis was again noted. Neuroimaging was not repeated with these two recurrences.
His fourth episode, at 29-months-of-age, was preceded by severe pain and inconsolable crying for 2 -3 days. The pain resolved with the onset of left partial oculomotor paresis, which became complete within two days. The left pupil response was also sluggish with this episode, which had not been noted with previous events. Repeat MRI again showed enhancement and thickening of the cistern portion of left oculomotor nerve. His symptoms resolved over 2 -3 weeks, longer than with previous episodes.
At the age of 6 years, he continues to have periodic recurrence of complete left oculomotor paresis, with each episode taking longer to recuperate. He also has developed migraine without aura. Pizotifen therapy has proven beneficial for his migraine but has not altered the frequency of his ophthalmoplegic migraine. He has developed evidence of permanent neurological damage with relative mydriasis which does reacts well to light. No residual ptosis or ocular paresis are present.
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Case 3
A healthy, 16-year-old female presented with abrupt onset right pupil dilatation, noted upon morning awakening. She had no associated change in visual acuity. She had noted a throbbing, right-sided headache with photophobia for two days. There was no associated nausea or vomiting, her headache had been similar to previous headaches which had occurred at roughly two-week intervals. She had no recent illness or trauma. Medical history revealed mild iron deficiency anemia and acne (treated with minocycline for four years). She was also taking an oral contraceptive agent. Examination showed mild obesity. The right pupil was dilated 5 mm and was unreactive to light. The left pupil was 3 mm and briskly reactive. Her visual acuity and field testing were normal. Her extraocular eye movements were normal and conjugate. There was no ptosis. Her fundoscopic exam was normal with no evidence of papilloedema. Her neurological exam was otherwise intact. Her CBC and ESR were normal. Initial CT head and MRI/MRA head without enhancement were normal. Repeat MRI head with gadolinium completed two weeks later, revealed definite enhancement of the cistern portion of the right oculomotor nerve. She did not receive prednisone therapy and her symptoms completely resolved within weeks.
She has gone 18 months without recurrence.
LITERATURE REVIEW
The initial episode of ophthalmoplegic migraine (OM) has been reported as early as age 3 months 6 ( Table 1 ). The mean and median age at the initial episode was 4.2 and 2 years respectively. Gender showed a slight female predilection: 25 females and 15 males (Table 2) .
Headache was a variable and inconsistent feature of ophthalmoplegic migraine. Headache, eye pain and/or irritability were not present during the initial episode of ophthalmoplegia in at least ten cases (25%). Seven patients exhibited headache only after recurrent episodes, and three did not develop irritability or headache despite multiple attacks. 4, 15 The three patients demonstrating ophthalmoplegia without headache were included in the review as they met all other diagnostic criteria and demonstrated reversible enhancement of the affected cranial nerve. We caution that the initial pain-free episodes of OM may in fact be underestimated. There may be a tendency for physicians to under-report such cases (as they do not fit the current definition of OM). Furthermore, several of the cases in our review found the earlier or initial episodes of ophthalmoplegia to also be less clinically apparent and persist for shorter durations.
When present, headache typically preceded onset of ocular symptoms by several days. Only one report 16 described headache developing five days after onset of ptosis. Head pain has been described as sharp retro-orbital pain 6 or inner-canthus eye pain (Case 1). The more "typical" migraine headache (throbbing pain in the frontal, retro-orbital or temporal regions) appears more often among adolescent and adult OM patients. [17] [18] [19] Associated "migraine symptoms" (nausea, vomiting, photophobia) were present in only 12 patients (35%).
Fifteen patients (37%) had a first-degree family member with migraines with an additional five (12%) having only seconddegree family member with migraine.
Oculomotor nerve (CN 3) was the most commonly involved. Isolated oculomotor nerve involvement was noted in 38 (95%) of cases. One patient demonstrated an isolated right abducens nerve involvement; 20 another, involvement of the left oculomotor and abducens nerve. 6 Without exception, recurrent episodes always affected the same cranial nerve and recurred on the same side.
Symptom onset was most often "abrupt" (ie. symptoms noted upon awakening); four patients however, reported gradual onset of ocular symptoms (ie. taking 24 hours 21 to as long as 7-10 days 15 to slowly progress to maximum ocular symptoms).
Recurrent episodes were noted to have a greater likelihood of 1) longer time for symptom resolution, 2) more severe or pronounced ocular symptoms and 3) resulting in permanent neurological sequelae.
The median time for symptom resolution of the initial episode was three weeks, with a range of "hours" 22 to three months. 13 All patients did eventually demonstrate complete symptom resolution after the initial episode. Twenty patients (50%) required ≥ 3 weeks for complete symptom resolution. In some cases recurrent episodes persisted for longer durations, 4, 16, 22 although it should be noted that such cases did not employ corticosteroid treatment.
Recurrent episodes may become increasingly severe. This was noted in our patient (Case 2), similar to other reports of initially partial transient ophthalmoplegia progressing to complete ophthalmoplegia with recurrent episodes. 16, 22 The interval between initial and recurrence of ophthalmoplegia varied from as little as weeks, 2 to up to 5-7 years. [22] [23] [24] Permanent neurological sequelae after repeated episodes have been reported in 12 (30%) of cases. The deficits ranged from permanent residual oculomotor weakness, 25 permanent mydriasis, 22, 26 to permanent, nearly total oculomotor paralysis. 23 A report of persistent abducens nerve palsy with recurrent episodes also exists. 27 Prednisone has been used frequently for treatment of ophthalmoplegic migraine.
Six reports clearly document a dramatic decrease in the time to symptom resolution with prednisone compared to the initial episode where prednisone had not been used. 6, 8, 20, 23, 25, 28 Kandt 28 documented a rapid response to prednisone therapy followed by "relapse" of ophthalmoplegia when steroids were abruptly discontinued after eight days. Symptoms again rapidly resolved with treatment reinstitution, there was no further recurrence with a more gradual taper. Prednisone has also been reported to have a possible abortive role when taken at the earliest sign of symptom onset. 20 Only one report failed to demonstrate a beneficial effect from prednisone therapy, 4 although the dose and timing of therapy in this case was unclear.
Magnetic resonance imaging with gadolinium enhancement was completed in 21/40 patients. Eighteen (86%) demonstrated enhancement of the affected cranial nerve during the acute episode of ophthalmoplegia which, when repeated during the convalescent phase, showed resolution. Cranial nerve thickening [1] indicates CT head normal, [2] indicates that MRI was not done for initial episode, but was completed during a subsequent, recurrent episode, [3] indicates MRI without gadolinium was normal, [4] indicates MRI without gadolinium showed no enhancement but CN appeared thickened was also noted on both MRI and CT head among patients that had experienced recurrent episodes. 23 The MR without enhancement was completed for five (one showed thickening from prepontine cistern to cavernous sinus, other studies were unremarkable), and the CT head was completed for eight patients. Six patients did not receive neuroimaging.
Two of the patients had only a single episode of ocular symptoms with the episodes occurring at age 18yrs 17 and 16yrs (Case 3). These patients otherwise fit the established criteria: headache present and absence of other demonstrable causes of transient, reversible ocular symptoms. Furthermore, they both exhibited MRI enhancement of cisternal portion of the affected nerve which showed resolution with repeat convalescent imaging. As such they were also included in the analysis.
DISCUSSION
Our cases and previous published cases had the following features that would not be expected in a primary migrainous condition: 1) prolonged time for symptom resolution to occur (median time, three weeks); 2) recurrent episodes showing increasingly severe ocular nerve involvement and longer duration of attacks; 3) permanent neurological sequelae with recurrent episodes (30% patients); 4) rapid improvement and shortened duration with corticosteroid therapy; 5) a report of ophthalmoplegia "relapse" upon withdrawal of short-course of steroid therapy and; 6) transient, reversible MRI contrast enhancement of the affected cranial nerve (86% patients receiving enhanced MR studies). These features suggest that ophthalmoplegic migraine shows clinical and radiographic features of a recurrent inflammatory cranial neuropathy.
Headache description and progression would favour inflammation rather than migraine, as headache and irritability were absent in 25% of patients at the time of initial ocular symptoms. Initially, when headache was present, it was often described as retro-orbital, eye or inner canthus pain, reminiscent of the ocular pain described in patients with optic neuritis. Headache became a more reliable feature with recurrent attacks, assuming a more typical migrainous pattern at that time.
These cases are readily differentiated from Tolosa-Hunt syndrome by the lack of involvement of the cavernous sinus (34/40 had CT and/or MR imaging), instead showing consistent involvement of the cisternal portion of oculomotor nerve in all cases where enhancement was identified.
The inflammatory theory of migraine 29 proposes that a chemical mediator may activate trigeminovascular axons resulting in neuropeptide release and a subsequent sterile inflammatory response. It is only with orthodromic conduction along trigeminovascular fibres to higher cortical structures that nociceptive registration and perception is thought to occur.
Local inflammation could also account for the clinical variability demonstrated in this condition. We are in agreement with Vijayan 10 that the variability in pupillary involvement (pupillary response spared in 21%, only partial involvement in at least 28%), does not favour vascular compression as a model for OM. In fact, reports of vascular changes during the active phase of OM, noted with cerebral angiogram, 9 may be the consequence (due to inflammation) rather than the cause of OM. Two patients with early contrast MR imaging that failed to show cranial nerve enhancement, 30 nevertheless demonstrated decreased perfusion on SPECT scan, an imaging feature which may be in keeping with local inflammation and edematous change.
If the ophthalmoplegia does result from an inflammatory cranial neuropathy, we hypothesize that it may predispose some patients (particularly with recurrent episodes) to develop headache or migraine. This is supported by the 70% of initially "headache-free patients developing migraine only with OM recurrence. There is increasing evidence that classic migraine may in fact be viewed as a neurogenic inflammatory disorder rather than a primary disorder of vascular smooth muscle. 31 Carlow 13 hypothesized that a similar inflammatory process, with the associated release of vasoactive neuropeptides and proinflammatory mediators, may activate the trigeminovascular system and give rise to migraine. Our findings lend further support to his hypothesis.
Our review provides clinical and radiographic support that "ophthalmoplegic migraine" is a recurrent inflammatory cranial neuropathy. Headache is an important, but often secondary feature of this condition. As such, classifying this condition as a migraine variant may have the disadvantageous result of delaying or taking an initial "wait and watch" approach with regard to treatment. Prompt corticosteroids therapy has proven beneficial at decreasing the duration of symptoms in the majority of OM cases where it has been used. This raises the important question as to whether corticosteroids may have a role at arresting the pattern of increasing clinical severity or avoiding permanent neurological deficit which is seen in a third of patients with recurrent episodes. On this basis, we advocate the reclassification of ophthalmoplegic migraine as a recurrent cranial neuropathy typically associated with secondary migraine.
